[1] Jemal A. Global Cancer Statistics. Cancer. 2011. 6(2): 69-90.
[2] Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013. 132(5): 1133-45.
[3] Ohm SBBaJE. Epigenetic gene silencing in cancer - A mechanism for early oncogenic pathway addiction. Cancer. 2006. 6: 107-116.
[4] Saadallah-Kallel A, Abdelmaksoud-Dammak R, Triki M, et al. Clinical and prognosis value of the CIMP status combined with MLH1 or p16 INK4a methylation in colorectal cancer. Med Oncol. 2017. 34(8): 147.
[5] Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology. 2000. 119(3): 854-65.
[6] Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut. 2007. 56(11): 1564-71.
[7] Thibodeau SN. Microsatellite instability in colorectal cancer: Different mutator phenotypes and
the principal involvement of hMLH1. Cancer Res. 1998. 58: 1713-1718.
[8] Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 2009. 455(6): 485-94.
[9] Verrico FZ&LR&M. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: Implications for molecular diagnosis. Tumor Biol. 2014. 10.
[10] Li J WZ, Cao S. A pilot study on clinicopathological features and intestinal microflora changes in colorectal cancer patients born over a nine-year period encompassing three years before and after the Great Chinese famine. Cancer Epidemiol. Cancer Epidemiol. 2019. 59: 166-172.
[11] Issa J. CpG island methylator phenotype in cancer. NATURE REVIEWS | CANCER. 2004. 4(12): 988-93.
[12] Berg M, Søreide K. Genetic and epigenetic traits as biomarkers in colorectal cancer. Int J Mol Sci. 2011. 12(12): 9426-39.
[13] Toyota M. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A. 2002. 97(2): 710–715.
[14] Weisenberger DJ. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006. 38(7): 787-793.
[15] Haixing JV. CpG island methylator phenotype in sporadic colorectal cancers and its relationship with microsatellite instability. CHINA MODERN DOCTOR. 2013. 51(26): 51-53.
[16] van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut. 2002. 51(6): 797-802.
[17] Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004. 53(8): 1137-44.
[18] Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. Oncotarget. 2016. 7(29): 46158-46172.
[19] DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006. 72(7): 5069-72.
[20] Cole JR, Wang Q, Cardenas E, et al. The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res. 2009. 37(Database issue): D141-5.
[21] Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004. 23(1-2): 101-17.
[22] Derks S, Lentjes MH, Hellebrekers DM, de Bruine AP, Herman JG, van Engeland M. Methylation-specific PCR unraveled. Cell Oncol. 2004. 26(5-6): 291-9.
[23] JAMES G. H. Methylation-specific PCR: A novel PCR ssay for methylation status of CpG islands. Medical Sciences: Herman. 1996. 93: 9821-9826.
[24] Barault L, Charon-Barra C, Jooste V, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008. 68(20): 8541-6.
[25] Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002. 123(6): 1804-11.
[26] White JR, Nagarajan N, Pop M. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol. 2009. 5(4): e1000352.
[27] Waterland RA, Michels KB. Epigenetic epidemiology of the developmental origins hypothesis. Annu Rev Nutr. 2007. 27: 363-88.
[28] Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005. 102(30): 10604-9.
[29] Feinberg AP. The epigenetic progenitor origin of human cancer. NATURE REVIEWS. 2006. 7: 21-33.
[30] Grady WM. Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans. 2005. 33(Pt 4): 684-8.
[31] Clarke MF. Epigenetic regulation of normal and cancer stem cells. Ann N Y Acad Sci. 2005. 1044: 90-3.
[32] Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005. 129(3): 837-45.
[33] S Ogino MC, Kawasaki T. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006. 55: 1000–1006.
[34] Ogino S, Kawasaki T, Kirkner GJ, et al. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol. 2006. 210(2): 147-54.
[35] Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol. 2007. 38(4): 614-20.
[36] Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction. Nat Rev Cancer. 2006. 6(2): 107-16.
[37] Nagasaka T. Colorectal Cancer With Mutation in BRAF, KRAS, and Wild-Type With Respect to Both Oncogenes Showing Different Patterns of DNA Methylation. J Clin Oncol. 2004. 22(22): 4584-4594.
[38] 2005. Colorectal Cancers with the Uncommon Findings of KRAS Mutation and Microsatellite Instability. Cytogenet Genome Res. .
[39] Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res. 2003. 9(8): 2898-903.
[40] Phipps AI. Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival. Gastroenterology. 2014. 14.
[41] Cha Y, Kim KJ, Han SW, et al. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. Br J Cancer. 2016. 115(2): 164-71.
[42] Barault L. Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases. Cancer Res. 2008. 68(20): 8541-8546.
[43] Jia M, Jansen L, Walter V, et al. No association of CpG island methylator phenotype and colorectal cancer survival: population-based study. Br J Cancer. 2016. 115(11): 1359-1366.
[44] Zlobec I, Bihl MP, Foerster A, Rufle A, Lugli A. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology. 2012. 61(5): 777-87.
[45] Li X, Hu F, Wang Y, et al. CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China. Biomed Res Int. 2014. 2014: 236361.
[46] Jia M, Gao X, Zhang Y, Hoffmeister M, Brenner H. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics. 2016. 8: 25.
[47] Akiyama S, Kikuchi D, Mitani T, et al. A case of mucinous adenocarcinoma in the setting of chronic colitis associated with intestinal spirochetosis and intestinal stricture. Medicine (Baltimore). 2015. 94(4): e493.
[48] Berg M. Inflfluence of Microsatellite Instability and KRAS and BRAF Mutations on Lymph Node Harvest in Stage I-III Colon Cancers. Mol Med. 2013. 19: 286-293.
[49] Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006. 8(5): 582-8.
[50] Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016. 65(12): 1973-1980.
[51] Soucek LF&JS&ME&P. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014. 2018(3).
[52] Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res. 2003. 9(9): 3362-8.
[53] Lucci-Cordisco E. The use of microsatellite instability, mmunohistochemistry and other variables in determining the clinical signifificance of MLH1 and MSH2 unclassifified variants in Lynch syndrome. Cancer Biomark. 2006. 26(201).
[54] Vlaykova T. Microsatellite instability and promoter hypermethylation of MLH1 and MSH2 in patients with sporadic colorectal cancer. Journal of B.u.on. Official Journal of the Balkan Union of Oncology. 2011. 16(2).
[55] Maija R.J. Kohonen-Corish JJD. Low Microsatellite Instability Is Associated With Poor rognosis in Stage C Colon Cancer. J Clin Oncol. 2006. 23(10): 2318-2324.